Teva Expects Launches To Hold North American Generics Sales At $4bn Per Year
With a roster of launches planned over coming months, Teva is confident it can keep returning sales by its North American Generics operation in the region of $1bn per quarter.
You may also be interested in...
Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.
Pfenex remains hopeful of receiving US approval for its teriparatide hybrid rival to Eli Lilly’s Forteo in October this year. But commercial partner Alvogen may have to wait for a therapeutic equivalence rating to the osteoporosis original.
Teva’s finance chief Mike McClellan is leaving the company in November. But he maintains his departure is solely due to personal reasons.